+ Watch EXAS
on My Watchlist
An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.
Exact's share price seems to be getting ahead of itself yet again as the Cologuard trial enters the early stages of an enrollment process that will likely extend at least another 12 months. That means topline data is unlikely before 2013, and the stock remains vulnerable to broad market declines. Personally, I believe we're headed for a doozy of a decline within the next few months. 435M is a hefty market cap for a company whose pipeline consists of a single unproven laboratory assay.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions